EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis

Yukio Tonozuka iD, Hiroshi Tanaka, Kazumi Nomura, Kazuya Sakaguchi, Junpei Soeda, Yoshihide Kakimoto

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-023-04609-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Yukio Tonozuka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, 1-1 Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, …. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Skin Neoplasms, Aminopyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Peripheral T-cell lymphoma (PTCL) is an aggressive disease with a poor prognosis. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent, has been approved for the treatment of PTCL. We evaluated a new effective combination partner of BV using non-clinical approaches that could potentially identify agents capable of improving survival times for patients with PTCL.

Methods

A high-throughput screening test was used to select the most synergistic partner of BV from 14 candidate drugs that were under development or available in clinical practice for PTCL. HH cells, originating from an aggressive cutaneous T-cell lymphoma, were used as an experimental model of PTCL. Apoptotic effects of the synergistic partner of BV were further investigated in vitro and in vivo using HH-cell xenograft mice.

Results

Chidamide (tucidinostat), a novel histone deacetylase inhibitor, was found to have the greatest synergistic effect with BV on HH cells. The combined effects of chidamide and BV were demonstrated in a study of HH-cell xenograft mice; mean tumor size following combined treatment was 22% of that observed in the control group, compared with 71% and 58% following chidamide and BV monotherapy, respectively. Further investigations in vitro and in vivo revealed that the levels of an anti-apoptotic protein, Bcl-2, and a rate-limiting factor of DNA replication, CDC45 , were reduced in HH cells treated with chidamide combined with BV compared with the control group.

Conclusion

The use of chidamide in conjunction with BV may positively affect and enhance T-cellular apoptotic pathways without offsetting each other.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralLymphoma, T-CellSkin NeoplasmsAminopyridinesBenzamidesHumansAnimalsMiceBrentuximab VedotinApoptosisCell Proliferation

Stichwörter der Autor:innen

ApoptosisBcl-2Brentuximab vedotinCDC45ChidamideT-cell lymphoma

Substanzen

Brentuximab VedotinN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideAminopyridinesBenzamides

Autor:innen und Institutionen

  • Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, 1-1 Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan. yukio.tonozuka@takeda.com.
  • Integrated Biology, Integrated & Translational Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome Fujisawa, Kanagawa, 251-0012, Japan.
  • Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, 1-1 Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan.
  • Frontier Technology, Integrated & Translational Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome Fujisawa, Kanagawa, 251-0012, Japan.

ORCID-Profile: Yukio Tonozuka

Zitieren

APA

Tonozuka, Y., Tanaka, H., Nomura, K., Sakaguchi, K., Soeda, J., & Kakimoto, Y. (2024). The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04609-5

Vancouver

Tonozuka Y, Tanaka H, Nomura K, Sakaguchi K, Soeda J, Kakimoto Y. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-023-04609-5

BibTeX
@article{Tonozuka2024,
  author = {Tonozuka, Yukio and Tanaka, Hiroshi and Nomura, Kazumi and Sakaguchi, Kazuya and Soeda, Junpei and Kakimoto, Yoshihide},
  title = {The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-023-04609-5}
}
Kostenlos starten →